3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Dermatologic
1
Conditions
Hodgkin Disease
33
Lymphoma
17
Lymphoma, Large-Cell, Anaplastic
15
Hematologic Diseases
13
Lymphoma, Non-Hodgkin
10
Recurrence
9
Lymphoma, T-Cell
7
Lymphoma, T-Cell, Peripheral
6
Lymphoma, Large B-Cell, Diffuse
5
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
4
Lymphoma, B-Cell
4
Neoplasms
3
Mycosis Fungoides
3
Lymphoma, T-Cell, Cutaneous
3
Lymphatic Diseases
3
Leukemia
3
Immunoblastic Lymphadenopathy
3
Sezary Syndrome
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasms, Germ Cell and Embryonal
2
Neoplasms by Histologic Type
2
Lymphoproliferative Disorders
2
Lymphoma, Extranodal NK-T-Cell
2
Leukemia, Myeloid, Acute
2
Immunoproliferative Disorders
2
Immune System Diseases
2
Enteropathy-Associated T-Cell Lymphoma
2
Waldenstrom Macroglobulinemia
1
Testicular Neoplasms
1
Nonseminomatous germ cell tumor
1
Interventions
Methotrexate
1
Brentuximab Vedotin
1
Bexarotene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Lymphoma, Primary Cutaneous Anaplastic Large Cell
×
Brentuximab Vedotin
×
Clear all
NCT01578499
2021-01-05
ALCANZA
Takeda
Phase 3
Completed
131 enrolled
24 charts